(function(){ var content_array=["

关于安必速<\/u><\/b>®<\/sup><\/p> \n

安必速®<\/sup>是两性霉素B的小球型单层脂质体,是用于系统性真菌治疗的唯一真正脂质体。安必速®<\/sup>适用于发热、中性粒细胞减少的真菌感染患者的经验性抗真菌治疗;对传统两性霉素B的治疗无反应或者因为肾功能损害无法耐受的曲霉属、念珠菌属和\/或隐球菌属感染患者;以及用于内脏利什曼病的治疗。<\/p> \n

关于吉利德科学<\/u><\/b><\/p> \n

吉利德科学是一家生物制药公司,成立三十多年来,探索并实现了多个医学上曾认为不可能实现的突破,旨在为公众创造一个更健康的世界。公司致力于推动药物革新,以预防和治疗HIV、病毒性肝炎和癌症等可能威胁生命的疾病。吉利德在全世界超过38个国家和地区运营,总部位于美国加利福尼亚州福斯特市。<\/p> \n

2017年,吉利德科学开始在中国的商业运营,致力于在病毒学及肿瘤学这些可危及生命的疾病领域为中国患者提供创新治疗手段及方案,创造更健康的中国。如今,我们已将慢性乙型肝炎、丙型肝炎、HIV防、治及抗真菌领域的十个全球领先的药物引入中国,其中,八个药物已被列入国家医保目录,让更多患者接受全球领先药物治疗,重回健康生活成为可能。<\/p> \n

\n \n \n \n \n \n \n \n \n \n \n

[1] 适应症详见说明书<\/span><\/p> <\/td> \n <\/tr> \n

[2] Min Liu, Meiwan Chen & Zhiwen Yang. Design of amphotericin B oral formulation for antifungal therapy, Drug Delivery. 2017,24:1, 1-9, DOI: 10.1080\/10717544.2016.12258<\/span><\/p> <\/td> \n <\/tr> \n

[3] Risk-based Estimate of Human Fungal Disease Burden, China. Emerging Infectious Diseases. 2020:2141<\/span><\/p> <\/td> \n <\/tr> \n

[4] 中国侵袭性曲霉菌病流行病学现状. 2018:57<\/span><\/p> <\/td> \n <\/tr> \n

[5] Lancet. 2007 May 5;369(9572):1519-1527<\/span><\/p> <\/td> \n <\/tr> \n

[6] N Engl J Med 1999;340:764-71<\/span><\/p> <\/td> \n <\/tr> \n

[7] Jenks JD, Gangneux JP, Schwartz IS, Alastruey-Izquierdo A, Lagrou K, Thompson Iii GR, Lass-Flörl C, Hoenigl M; European Confederation of Medical Mycology (ECMM) Council Investigators. Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. J Fungi (Basel). 2020 Oct 11;6(4):216. doi: 10.3390\/jof6040216. PMID: 33050598<\/span><\/p> <\/td> \n <\/tr> \n

[8] Ademe, M. (2020). Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges. Frontiers in Cellular and Infection Microbiology, 10. doi:10.3389\/fcimb.2020.00469<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

 <\/p>"]; $("#dvExtra").html(content_array[0]);})();